Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Angiography | Research article

Clinical utility of serum cystatin C for prediction of multi-vessel disease by coronary angiography in type 2 diabetes mellitus patients with normal renal function

Authors: Shaoyi Wang, Qiaohui Liu, Fangfang Guo, Xiaocong Zhou, Jie Shi, Qing Xie

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

The aim of this study was to evaluate whether serum cystatin C could serve as a predictor of multivessel coronary artery disease identified by coronary angiography in type 2 diabetes patients with normal renal function and to suggest the cutoff point of serum cystatin C for predicting multivessel disease.

Methods

Serum cystatin C concentrations were measured by using particle-enhanced immunonephelometric assays before coronary angiography in 135 consecutive type 2 diabetes patients and 179 nondiabetic patients with normal renal function. Routine anthropometric and serologic data were collected. The severity of multivessel disease was assessed with the Gensini score after coronary angiography. The associations of serum cystatin C with the Gensini score were investigated, and the independent risk factors associated with multivessel disease were assessed.

Results

Serum cystatin C and the Gensini score were significantly elevated in diabetes patients. Cystatin C had a positive correlation with Gensini score. A multiple logistic regression analysis demonstrated that cystatin C was independently associated with the presence of multivessel disease (the OR score is 2.21, P = 0.003). Based on the ROC curve, a cystatin C level of 0.865 mg/L showed 67.7% sensitivity and 76.3% specificity with an AUC of 0.748 in diabetes patients for detecting multivessel disease.

Conclusion

Serum cystatin C is significantly correlated with the presence of multivessel disease, suggesting that cystatin C might be utilized as a screening tool for predicting multivessel disease in type 2 diabetes mellitus patients with normal renal function.
Literature
1.
go back to reference Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prevent Med. 2006;30(5):371–7.CrossRef Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prevent Med. 2006;30(5):371–7.CrossRef
2.
go back to reference Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.CrossRef Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.CrossRef
3.
go back to reference Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114–26.CrossRef Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114–26.CrossRef
4.
go back to reference Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol. 2007;49(6):631–42.CrossRef Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol. 2007;49(6):631–42.CrossRef
5.
go back to reference Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio heart study. Diabetes Care. 1998;21(7):1167–72.CrossRef Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio heart study. Diabetes Care. 1998;21(7):1167–72.CrossRef
6.
go back to reference Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.CrossRef Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.CrossRef
7.
go back to reference Filler G, Bokenkamp A, Hofmann W, Le BT, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2005;38(1):1–8. Filler G, Bokenkamp A, Hofmann W, Le BT, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2005;38(1):1–8.
8.
go back to reference Hsiao PG, Hsieh CA, Yeh CF, Wu HH, Shiu TF, Chen YC, Chu PH: Early prediction of acute kidney injury in patients with acute myocardial injury. Journal of critical care 2012, 27(5):525.e521–527. Hsiao PG, Hsieh CA, Yeh CF, Wu HH, Shiu TF, Chen YC, Chu PH: Early prediction of acute kidney injury in patients with acute myocardial injury. Journal of critical care 2012, 27(5):525.e521–527.
9.
go back to reference Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142(7):497–505.CrossRef Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142(7):497–505.CrossRef
10.
go back to reference Hoke M, Pernicka E, Niessner A, Goliasch G, Amighi J, Koppensteiner R, Minar E, Mlekusch W, Rumpold H, Wagner O, et al. Renal function and long-term mortality in patients with asymptomatic carotid atherosclerosis. Thromb Haemost. 2012;107(1):150–7.CrossRef Hoke M, Pernicka E, Niessner A, Goliasch G, Amighi J, Koppensteiner R, Minar E, Mlekusch W, Rumpold H, Wagner O, et al. Renal function and long-term mortality in patients with asymptomatic carotid atherosclerosis. Thromb Haemost. 2012;107(1):150–7.CrossRef
11.
go back to reference Qing X, Furong W, Yunxia L, Jian Z, Xuping W, Ling G. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol. 2012;11:108.CrossRef Qing X, Furong W, Yunxia L, Jian Z, Xuping W, Ling G. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol. 2012;11:108.CrossRef
12.
go back to reference Surendar J, Indulekha K, Aravindhan V, Ganesan A, Mohan V. Association of cystatin-C with metabolic syndrome in normal glucose-tolerant subjects (CURES-97). Diabetes Technol Ther. 2010;12(11):907–12.CrossRef Surendar J, Indulekha K, Aravindhan V, Ganesan A, Mohan V. Association of cystatin-C with metabolic syndrome in normal glucose-tolerant subjects (CURES-97). Diabetes Technol Ther. 2010;12(11):907–12.CrossRef
13.
go back to reference Bokenkamp A, van Wijk JA, Lentze MJ, Stoffel-Wagner B. Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem. 2002;48(7):1123–6.CrossRef Bokenkamp A, van Wijk JA, Lentze MJ, Stoffel-Wagner B. Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem. 2002;48(7):1123–6.CrossRef
14.
go back to reference Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416–21.CrossRef Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416–21.CrossRef
15.
go back to reference Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63(5):1944–7.CrossRef Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63(5):1944–7.CrossRef
16.
go back to reference Diagnosis and classification of diabetes mellitus. Diabetes care 2008, 31 Suppl 1:S55–60. Diagnosis and classification of diabetes mellitus. Diabetes care 2008, 31 Suppl 1:S55–60.
17.
go back to reference National High Blood Pressure Education P. In: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. edn. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004. National High Blood Pressure Education P. In: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. edn. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004.
18.
go back to reference AS L, J C, H T, T G, La I. Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol. 2020;16(1):51–64.CrossRef AS L, J C, H T, T G, La I. Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol. 2020;16(1):51–64.CrossRef
19.
go back to reference Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.CrossRef Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.CrossRef
20.
go back to reference Ichimoto E, Jo K, Kobayashi Y, Inoue T, Nakamura Y, Kuroda N, Miyazaki A, Komuro I. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circulation J. 2009;73(9):1669–73.CrossRef Ichimoto E, Jo K, Kobayashi Y, Inoue T, Nakamura Y, Kuroda N, Miyazaki A, Komuro I. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circulation J. 2009;73(9):1669–73.CrossRef
21.
go back to reference Silva D, Cortez-Dias N, Jorge C, Marques JS, Carrilho-Ferreira P, Magalhaes A, Martins SR, Goncalves S, da Silva PC, Fiuza M, et al. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol. 2012;109(10):1431–8.CrossRef Silva D, Cortez-Dias N, Jorge C, Marques JS, Carrilho-Ferreira P, Magalhaes A, Martins SR, Goncalves S, da Silva PC, Fiuza M, et al. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol. 2012;109(10):1431–8.CrossRef
22.
go back to reference Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol. 2009;32(11):644–8.CrossRef Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol. 2009;32(11):644–8.CrossRef
23.
go back to reference Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28(15):1841–7.CrossRef Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28(15):1841–7.CrossRef
24.
go back to reference Retnakaran R, Connelly PW, Harris SB, Zinman B, Hanley AJ: Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatric nephrology (Berlin, Germany) 2007, 22(7):1007–1013. Retnakaran R, Connelly PW, Harris SB, Zinman B, Hanley AJ: Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatric nephrology (Berlin, Germany) 2007, 22(7):1007–1013.
25.
go back to reference Demircan N, Gurel A, Armutcu F, Unalacak M, Aktunc E, Atmaca H: The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Medical science monitor : international medical journal of experimental and clinical research 2008, 14(2):Cr97–101. Demircan N, Gurel A, Armutcu F, Unalacak M, Aktunc E, Atmaca H: The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Medical science monitor : international medical journal of experimental and clinical research 2008, 14(2):Cr97–101.
26.
go back to reference Vigil L, Lopez M, Condes E, Varela M, Lorence D, Garcia-Carretero R, Ruiz J. Cystatin C is associated with the metabolic syndrome and other cardiovascular risk factors in a hypertensive population. JASH. 2009;3(3):201–9.PubMed Vigil L, Lopez M, Condes E, Varela M, Lorence D, Garcia-Carretero R, Ruiz J. Cystatin C is associated with the metabolic syndrome and other cardiovascular risk factors in a hypertensive population. JASH. 2009;3(3):201–9.PubMed
27.
go back to reference Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121(5):426–32.CrossRef Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121(5):426–32.CrossRef
28.
go back to reference Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54(6):1335–40.CrossRef Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54(6):1335–40.CrossRef
29.
go back to reference Niccoli G, Conte M, Della Bona R, Altamura L, Siviglia M, Dato I, Ferrante G, Leone AM, Porto I, Burzotta F, et al. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis. 2008;198(2):373–80.CrossRef Niccoli G, Conte M, Della Bona R, Altamura L, Siviglia M, Dato I, Ferrante G, Leone AM, Porto I, Burzotta F, et al. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis. 2008;198(2):373–80.CrossRef
30.
go back to reference Koc M, Batur MK, Karaarslan O, Abali G. Clinical utility of serum cystatin C in predicting coronary artery disease. Cardiol J. 2010;17(4):374–80.PubMed Koc M, Batur MK, Karaarslan O, Abali G. Clinical utility of serum cystatin C in predicting coronary artery disease. Cardiol J. 2010;17(4):374–80.PubMed
31.
go back to reference Ahlstrom A, Tallgren M, Peltonen S, Pettila V. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol. 2004;62(5):344–50.CrossRef Ahlstrom A, Tallgren M, Peltonen S, Pettila V. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol. 2004;62(5):344–50.CrossRef
32.
go back to reference Beauvieux MC, Le Moigne F, Lasseur C, Raffaitin C, Perlemoine C, Barthe N, Chauveau P, Combe C, Gin H, Rigalleau V. New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care. 2007;30(8):1988–94.CrossRef Beauvieux MC, Le Moigne F, Lasseur C, Raffaitin C, Perlemoine C, Barthe N, Chauveau P, Combe C, Gin H, Rigalleau V. New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care. 2007;30(8):1988–94.CrossRef
33.
go back to reference Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. CJASN. 2010;5(9):1552–7.CrossRef Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. CJASN. 2010;5(9):1552–7.CrossRef
Metadata
Title
Clinical utility of serum cystatin C for prediction of multi-vessel disease by coronary angiography in type 2 diabetes mellitus patients with normal renal function
Authors
Shaoyi Wang
Qiaohui Liu
Fangfang Guo
Xiaocong Zhou
Jie Shi
Qing Xie
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01475-4

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue